Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Healing of erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily.
* **Pathological hypersecretory conditions:** 40 mg orally or intravenously twice daily, may be increased to a maximum of 80 mg intravenously or orally twice daily.
## Pediatric Dosing
* **Erosive esophagitis (ages 5-16 years):** 20 mg orally once daily for up to 8 weeks.
* **Erosive esophagitis (ages 1 month to <5 years):** 0.7 mg/kg orally once daily, not to exceed 40 mg daily, for up to 8 weeks.
* Dosing for pathological hypersecretory conditions in pediatric patients is not well-established.
## Dose Adjustments
* No specific dose adjustment is recommended for patients with hepatic impairment. However, the maximum daily dose should not exceed 40 mg orally.
* No specific dose adjustment is recommended for patients with renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of its formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and flatulence. Long-term use of PPIs may be associated with an increased risk of fractures, Clostridium difficile infection, vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** PPIs can decrease absorption of drugs like ketoconazole, itraconazole, iron salts, and certain protease inhibitors.
* **Methotrexate:** Co-administration with PPIs may increase methotrexate levels.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19 and may increase concentrations of drugs metabolized by this enzyme (e.g., clopidogrel, citalopram).
## Monitoring
* Monitor for signs and symptoms of Clostridium difficile-associated diarrhea.
* Consider monitoring serum magnesium levels, especially in patients on long-term therapy or concomitant diuretic use.
* Assess for efficacy and need for continued therapy.
## Clinical Pearls
* Intravenous formulation is generally reserved for patients unable to take oral medication.
* Oral pantoprazole should be taken at least 1 hour before a meal.
* Consider the risks and benefits of long-term PPI use, especially in elderly patients or those with risk factors for fractures or infections.
This information is intended for clinical decision-making and does not replace a thorough review of the current prescribing information. Always consult the most up-to-date product monograph or reliable drug information resource before initiating or modifying therapy.
